JP2012507033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507033A5 JP2012507033A5 JP2011534536A JP2011534536A JP2012507033A5 JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5 JP 2011534536 A JP2011534536 A JP 2011534536A JP 2011534536 A JP2011534536 A JP 2011534536A JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5
- Authority
- JP
- Japan
- Prior art keywords
- spectrum
- monoclonal antibody
- growth factor
- factor receptor
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001228 spectrum Methods 0.000 claims 6
- 102100010782 EGFR Human genes 0.000 claims 4
- 101700039191 EGFR Proteins 0.000 claims 4
- 201000011231 colorectal cancer Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000001819 mass spectrum Methods 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 108010022830 Cetuximab Proteins 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 108010061219 Panitumumab Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000007635 classification algorithm Methods 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000007781 pre-processing Methods 0.000 claims 1
Claims (7)
- 結腸直腸癌（ＣＲＣ）患者について、ＥＧＦＲ経路を標的にするモノクローナル抗体である上皮増殖因子受容体阻害剤による治療が有効である可能性が高いかどうかを決定する方法であって、
ａ）該ＣＲＣ患者より採取した血液に基づくサンプルから質量スペクトルを得ること；
ｂ）ステップａ）にて得られた質量スペクトルに、１つ以上の所定の前処理ステップを行うこと；
ｃ）ステップｂ）にて質量スペクトルに前処理ステップを行った後、１つ以上の所定のｍ／ｚ範囲で、該スペクトルの選択された特徴の積分強度値を得ること；および
ｄ）モノクローナル抗体である該上皮増殖因子受容体阻害剤による治療が有効である可能性が高いか低いかについて該ＣＲＣ患者を同定するために、他の癌患者より採取した血液に基づくサンプルから作成したクラス標識したスペクトル（class-labeled spectra）を含む訓練集合（training set）を用いる分類アルゴリズムに、ステップｃ）にて得られた値を用いること
の各ステップを含む方法。 - １つ以上のｍ／ｚ範囲が、
５７３２〜５７９５
５８１１〜５８７５
６３９８〜６４６９
１１３７６〜１１５１５
１１４５９〜１１５９９
１１６１４〜１１７５６
１１６８７〜１１８３１
１１８３０〜１１９７６
１２３７５〜１２５２９
２３１８３〜２３５２５
２３２７９〜２３６２２および
６５９０２〜６７５０２
からなるｍ／ｚ範囲の群から選択される１つ以上のｍ／ｚ範囲を含む、請求項１の方法。 - 質量スペクトルがＭＡＬＤＩ質量分析計から得られたものである、請求項１の方法。
- 所定の前処理ステップが、バックグラウンド減算スペクトルを作成するバックグラウンド減算ステップ、およびバックグラウンド減算スペクトルの正規化を行う正規化ステップを含む、請求項１の方法。
- 訓練集合（training set）が非小細胞肺癌患者より得られた血液に基づくサンプルから作成したクラス標識したスペクトル（class-labeled spectra）を含む、請求項１の方法。
- モノクローナル抗体である上皮増殖因子受容体阻害剤がセツキシマブまたはその均等物を含む、請求項１の方法。
- モノクローナル抗体である上皮増殖因子受容体阻害剤がパニツムマブまたはその均等物を含む、請求項１の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/321,394 | 2009-01-20 | ||
| US12/321,394 US7858390B2 (en) | 2006-03-31 | 2009-01-20 | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| PCT/US2009/006267 WO2010085234A1 (en) | 2009-01-20 | 2009-11-20 | Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507033A JP2012507033A (ja) | 2012-03-22 |
| JP2012507033A5 true JP2012507033A5 (ja) | 2012-05-10 |
| JP4997345B2 JP4997345B2 (ja) | 2012-08-08 |
Family
ID=41571343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534536A Expired - Fee Related JP4997345B2 (ja) | 2009-01-20 | 2009-11-20 | Ｅｇｆｒ経路を標的にする薬物による治療のための結腸直腸癌患者の選択 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7858390B2 (ja) |
| EP (1) | EP2347261B1 (ja) |
| JP (1) | JP4997345B2 (ja) |
| KR (1) | KR101131231B1 (ja) |
| AU (1) | AU2009338173B2 (ja) |
| CA (1) | CA2744394A1 (ja) |
| ES (1) | ES2392805T3 (ja) |
| HK (1) | HK1156696A1 (ja) |
| IL (1) | IL211944A (ja) |
| TW (1) | TWI366671B (ja) |
| WO (1) | WO2010085234A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906342B2 (en) * | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| US7736905B2 (en) | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| CN102770760A (zh) * | 2010-02-24 | 2012-11-07 | 佰欧迪塞克斯公司 | 利用质谱分析选择施用治疗剂的癌症患者 |
| JP2014505257A (ja) | 2011-01-28 | 2014-02-27 | バイオデシックス・インコーポレイテッド | ホルモン療法および組み合わせ療法のための転移性乳癌患者の選択の予測試験 |
| SG11201408652SA (en) | 2012-06-26 | 2015-01-29 | Biodesix Inc | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US8718996B2 (en) | 2012-07-05 | 2014-05-06 | Biodesix, Inc. | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents |
| TW201621315A (zh) | 2014-12-03 | 2016-06-16 | 拜歐迪希克斯公司 | 使用ｍａｌｄｉ－ｔｏｆ質譜分析以早期偵測高風險群中之肝細胞癌 |
| WO2017011439A1 (en) | 2015-07-13 | 2017-01-19 | Biodesix, Inc. | Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
| CA3011719A1 (en) | 2016-01-21 | 2017-07-27 | Protein Dynamic Solutions Llc | Method and system for spectral data analysis |
| US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
| WO2017176423A1 (en) | 2016-04-08 | 2017-10-12 | Biodesix, Inc. | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy |
| WO2018129301A1 (en) | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
| CA3085765A1 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103969449B (zh) | 2002-08-06 | 2016-11-23 | 约翰霍普金斯大学 | 用于检测卵巢癌的生物标记的用途 |
| AU2004248140A1 (en) * | 2003-05-30 | 2004-12-23 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
| US20050267689A1 (en) * | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
| US20050048547A1 (en) * | 2003-07-17 | 2005-03-03 | Hongyu Zhao | Classification of disease states using mass spectrometry data |
| CA2561535A1 (en) | 2004-03-30 | 2005-10-20 | Eastern Virginia Medical School | Lung cancer biomarkers |
| US20060029574A1 (en) * | 2004-08-06 | 2006-02-09 | Board Of Regents, The University Of Texas System | Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity |
| ES2398709T5 (es) * | 2005-06-28 | 2017-04-18 | Genentech, Inc. | Mutaciones en EGFR y KRAS para predecir la respuesta de un paciente al tratamiento con inhibidores de EGFR |
| WO2007109571A2 (en) * | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
-
2009
- 2009-01-20 US US12/321,394 patent/US7858390B2/en not_active Expired - Fee Related
- 2009-11-20 AU AU2009338173A patent/AU2009338173B2/en not_active Ceased
- 2009-11-20 ES ES09795836T patent/ES2392805T3/es active Active
- 2009-11-20 WO PCT/US2009/006267 patent/WO2010085234A1/en active Application Filing
- 2009-11-20 JP JP2011534536A patent/JP4997345B2/ja not_active Expired - Fee Related
- 2009-11-20 CA CA2744394A patent/CA2744394A1/en not_active Abandoned
- 2009-11-20 KR KR1020117007641A patent/KR101131231B1/ko not_active IP Right Cessation
- 2009-11-20 EP EP09795836A patent/EP2347261B1/en not_active Not-in-force
- 2009-12-16 TW TW098143181A patent/TWI366671B/zh not_active IP Right Cessation
-
2011
- 2011-03-24 IL IL211944A patent/IL211944A/en not_active IP Right Cessation
- 2011-10-14 HK HK11110985.3A patent/HK1156696A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507033A5 (ja) | ||
| JP2011513728A5 (ja) | ||
| CN109884302B (zh) | 基于代谢组学和人工智能技术的肺癌早期诊断标志物及其应用 | |
| Onaitis et al. | Prediction of long-term survival after lung cancer surgery for elderly patients in The Society of Thoracic Surgeons General Thoracic Surgery Database | |
| Van der Sar et al. | The smell of lung disease: a review of the current status of electronic nose technology | |
| WO2009049189A3 (en) | Methods for detecting major adverse cardiovascular and cerebrovascular events | |
| JP2015528110A5 (ja) | ||
| JP2013520681A5 (ja) | ||
| HK1103439A1 (en) | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment | |
| WO2007109881A8 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| US20170307535A1 (en) | Diagnosis of cancer | |
| JP2009538607A5 (ja) | ||
| NZ719474A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| JP2009534667A5 (ja) | ||
| WO2009074276A3 (en) | Marker panel for colorectal cancer | |
| EP2557413A3 (en) | Blood analysis apparatus and blood analysis method | |
| Mazzone et al. | Progress in the development of volatile exhaled breath signatures of lung cancer | |
| GB2494580A (en) | Method for diagnosing lung cancer | |
| WO2013016966A1 (zh) | 检测肺癌蛋白的质谱模型及构建方法 | |
| Aichler et al. | Proteomic and metabolic prediction of response to therapy in gastric cancer | |
| CN111710372A (zh) | 一种呼出气检测装置及其呼出气标志物的建立方法 | |
| Koopaie et al. | Salivary biomarkers in breast cancer diagnosis: a systematic review and diagnostic meta‐analysis | |
| EA201400131A1 (ru) | Новый классификатор для молекулярной классификации миеломной болезни | |
| Wang et al. | SERS spectroscopy and multivariate analysis of globulin in human blood | |
| Lin et al. | Diagnostic Potential for Circular RNAs in Gastric Carcinoma: a Meta-Analysis. |